Agonist News and Research

RSS
Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire publishes new study results on INTUNIV Extended-Release Tablets

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

VaxInnate licensed to use 3M Drug Delivery Systems' TLR agonists

VaxInnate licensed to use 3M Drug Delivery Systems' TLR agonists

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire's INTUNIV for treating ADHD now available in the U.S.

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Neurogen announces financial results for the third quarter of 2009

Neurogen announces financial results for the third quarter of 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Aerovance enrolls 540 patients in Phase 2b Aerovant clinical trial

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries net sales up 25%

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

NuPathe and SurModics sign a drug delivery technology license agreement

NuPathe and SurModics sign a drug delivery technology license agreement

New study results of INTUNIV presented at a major psychiatric medical meeting

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Third-quarter fiscal 2009 results announced by Adolor

Third-quarter fiscal 2009 results announced by Adolor

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Sosei Group announces Phase III trials update on NVA237 and QVA149

Sosei Group announces Phase III trials update on NVA237 and QVA149

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.